GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (TSE:4565) » Definitions » Gross Profit

Nxera Pharma Co (TSE:4565) Gross Profit : 円21,219 Mil (TTM As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Nxera Pharma Co Gross Profit?

Nxera Pharma Co's gross profit for the three months ended in Dec. 2024 was 円4,725 Mil. Nxera Pharma Co's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was 円21,219 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Nxera Pharma Co's gross profit for the three months ended in Dec. 2024 was 円4,725 Mil. Nxera Pharma Co's Revenue for the three months ended in Dec. 2024 was 円6,852 Mil. Therefore, Nxera Pharma Co's Gross Margin % for the quarter that ended in Dec. 2024 was 68.96%.

Nxera Pharma Co had a gross margin of 68.96% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Nxera Pharma Co was 99.95%. The lowest was 73.59%. And the median was 92.72%.

Warning Sign:

Nxera Pharma Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -4.6%.


Nxera Pharma Co Gross Profit Historical Data

The historical data trend for Nxera Pharma Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Gross Profit Chart

Nxera Pharma Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,081.00 16,779.00 14,643.00 9,664.00 21,219.00

Nxera Pharma Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,542.00 3,420.00 5,808.00 7,266.00 4,725.00

Competitive Comparison of Nxera Pharma Co's Gross Profit

For the Biotechnology subindustry, Nxera Pharma Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Gross Profit falls into.


;
;

Nxera Pharma Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Nxera Pharma Co's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=28835 - 7616
=21,219

Nxera Pharma Co's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=6852 - 2127
=4,725

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円21,219 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Nxera Pharma Co's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=4,725 / 6852
=68.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Nxera Pharma Co  (TSE:4565) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Nxera Pharma Co had a gross margin of 68.96% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Nxera Pharma Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co Business Description

Traded in Other Exchanges
Address
Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).

Nxera Pharma Co Headlines

No Headlines